Ticagrelor

  Ticagrelor is recommended as a firstline antithrombotic agent in patients with acute coronary syndromes.

  Ticagrelor is a direct-acting and reversible P2Y12-adenosine diphosphate receptor antagonist.

  Inhibition of adenosine uptake results in increased adenosine tissue concentrations.

  The effect of ticagrelor on sinoatrial and AV nodes is believed to be mediated by an increased tissue concentration of adenosine.




ECG abnormalities that may be seen in patients with under Ticagrelor therapy

  Sinus bradycardia

  Atrioventricular block

  Prolonged asystole

  QT interval prolongation




References (with links to full text and sample ECGs)

  Tex Heart Inst J 2019;46(3):203-206.

  Case Rep Cardiol 2019 Nov 7;2019:5984847. doi: 10.1155/2019/5984847. eCollection 2019

  HeartRhythm Case Rep 2018;4(11):527-529

  Case Rep Vasc Med. 2018 Apr 19;2018:9385017. doi: 10.1155/2018/9385017. eCollection 2018

  Ann Intern Med. 2018 Apr 17;168(8):602-603

  Cardiol Res 2017;8(3):123-127

  World J Clin Cases 2017;5(5):178-182

  Int J Cardiol 2016;214:21-22

  Int J Cardiol 2016;202:946-947

  Int J Cardiol 2015;182:379-380